Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $1,393,751 — Abstract: The goals of Scientific Project Two are the manufacturing and release of two cGMP saRNA/NLC HIV-1 Env-derived vaccine candidates and the establishment of an ICH-compliant stability program for these vaccines. The two vaccines consist of a self-amplifying RNA (saRNA) encoding two HIV-1 Env…
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $272,530 — SUMMARY The VIVA Clinical Core B provides the infrastructures needs to support standardized approaches for the recruitment, longitudinal retention and clinical characterization of human subjects enrolled in observational studies. The Core B will facilitate patient centered research through activitie…
Frederic D Bushman · UNIVERSITY OF PENNSYLVANIA · 2024 · $172,353 — SUMMARY- CORE B (GENOMICS CORE) Core B (Genomics Core) will provide key support to the mVACS team in Clostridioides difficile genome sequence analysis, antigen design, microbiome sequence analysis, routine statistical analysis, and high content data management. Core B will use advanced genomics-base…
Brendan Joseph Kelly · UNIVERSITY OF PENNSYLVANIA · 2024 · $215,035 — SUMMARY – CORE C (CLINICAL CORE) Core C (Clinical Core) will support the overall mVACS program goal to develop modified mRNA vaccines to eliminate C.difficile infection (CDI) by developing an infrastructure for CDI human subject identification, specimen biobanking, and metadata collection to study t…
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $668,200 — ABSTRACT – Project 2 Globally, about 600,000 young adults (15-24 years of age) became infected with HIV-1 in 2017. Young women age 15-19 years are most affected, and HIV-infection in this age group continue to rise. Therefore, a vaccine to prevent HIV acquisition in young adults remains a top priori…
Adolfo Garcia-Sastre · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $403,954 — Two years into the COVID-19 pandemic, SARS-CoV-2 infections are still responsible for huge economic losses, lockdowns and stressed health care systems worldwide. Different from the situation early during the pandemic, when the virus started circulating in the human population in the absence of pre-e…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $674,912 — Summary Circulating (tier 2) HIV-1 variants are highly resistant to antibody-mediated neutralization, making broadly effective vaccine design a major challenge. Encouragingly, work in our previous HIVRAD program demonstrated that Ab responses capable of cross-neutralizing multiple heterologous ti…
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $1,035,959 — Vaccine trials in non-human primates challenged with R5, tier 2 SHIVs have shown protection in the presence of high levels of non-neutralizing antibodies (NNAbs), and one of the 5 Phase IIb HIV-1 vaccine efficacy trials using alum (ALVAC/AIDSVAX in RV144) showed an estimated vaccine efficacy of 31%,…
Thomas Denny · DUKE UNIVERSITY · 2024 · $5,033,198 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
Philip Murphy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $11,205 — We have written an Animal Study Proposal that has been approved by the NIAID Animal Care and Use Committee. We have not yet begun research because the BSL3 and ABSL3 facilities were not open until summer 2020. We are awaiting approval of our proposal by the BSL3 review committee. In the 1st Year,…
Yasmine Belkaid · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $3,460,631 — In response to the SARS-CoV-2 pandemic we have made the technologies and platforms at CHI available for characterization of COVID-19 patient samples, as a priority ahead of our ongoing collaborative studies. By early April we had completed adaptation of our transcriptomic and flow cytometry platfor…
Bernard Lafont · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $947,283 — Viruses of the Coronaviridae family are enveloped viruses that possess a large (30kb), single-stranded, positive sense, RNA genome that infect a large number of mammals (alpha and beta coronaviruses) and birds (gamma coronaviruses). Four different seasonal coronaviruses (two alpha coronaviruses, 229…
OFER LEVY · BOSTON CHILDREN'S HOSPITAL · 2020 · $184,957 — PROJECT SUMMARY: From a cluster of respiratory illnesses in Wuhan, China, to a worldwide pandemic, the world has learned of a novel coronavirus (SARS-CoV-2) but little is known about the pathogenesis that leads to the disease termed “COVID”. Patients with SARS-CoV-2 infection range from asymptomatic…
Nirav Rati Bhakta · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $1,405,090 — PROJECT SUMMARY/ABSTRACT COVID-19, the pandemic illness caused by the novel virus SARS-CoV-2, is a serious respiratory illness that has high infectivity and a mortality rate that varies from <1% to up to 20% depending on underlying risk factors. Indeed, disease severity varies markedly based on reco…
OFER LEVY · BOSTON CHILDREN'S HOSPITAL · 2020 · $2,426,447 — IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC): Clinical and Data Coordinating Center (CDCC) Project summary In December 2019, a cluster of respiratory illness in Wuhan, China defined the onset of a global pandemic involving a novel coronavirus (SARS-CoV-2) with associated respiratory di…
FRED R HIRSCH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $680,221 — ADMINISTRATIVE CORE: ABSTRACT Our inter-institutional U54 Serological Sciences Center of Excellence (“U54”) Administrative Core provides scientific and administrative oversight for all of the U54’s Projects and Cores. It also provides the main interface with patient advocates, NCI program staff, ex…
Mitchel A Rosen · RBHS-SCHOOL OF PUBLIC HEALTH · 2020 · $15,850 — Abstract The New Jersey / New York Hazardous Materials Worker Training Center will provide training for essential works to respond and work safely when faced with exposure to COVID-19. The Center will provide train-the-trainer course via distance web conferencing to expand the knowledge of trainers …
Daniel W Fitzgerald · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $632,901 — The COVID-19 pandemic has now spread from high- and middle-income countries to low-income countries, including Haiti and Tanzania. The natural history of COVID-19 is unknown in low-income countries. We propose to study a combined cohort of 3,054 adults in Haiti and Tanzania to determine the attack r…
Karla J F Satchell · NORTHWESTERN UNIVERSITY AT CHICAGO · 2020 · $1,578,942 — The goal of the Structural Genomics Centers for Infectious Diseases is to apply state-of-the-art, high-throughput structural biology technologies to experimentally characterize the three-dimensional atomic structure of targeted proteins on the NIAID Category A-C priority pathogens list and organisms…
THOMAS DENNY · DUKE UNIVERSITY · 2020 · $573,990 — The NIAID Division of AIDS has a requirement for the conduct of quantitative viral RNA measurements for assessment of HIV/SIV vaccine efficacy in preclinical studies with nonhuman primates. The NIAID provides immunological and virological support for nonhuman primate studies conducted at NIAID’s Sim…